Hyperlipidemia primary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

For patient information click here

WikiDoc Resources for Hyperlipidemia primary prevention
Articles
Most recent articles on Hyperlipidemia primary prevention Most cited articles on Hyperlipidemia primary prevention Review articles on Hyperlipidemia primary prevention Articles on Hyperlipidemia primary prevention in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Hyperlipidemia primary prevention Images of Hyperlipidemia primary prevention Photos of Hyperlipidemia primary prevention Podcasts & MP3s on Hyperlipidemia primary prevention Videos on Hyperlipidemia primary prevention
Evidence Based Medicine
Cochrane Collaboration on Hyperlipidemia primary prevention Bandolier on Hyperlipidemia primary prevention TRIP on Hyperlipidemia primary prevention
Clinical Trials
Ongoing Trials on Hyperlipidemia primary prevention at Clinical Trials.gov Trial results on Hyperlipidemia primary prevention Clinical Trials on Hyperlipidemia primary prevention at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Hyperlipidemia primary prevention NICE Guidance on Hyperlipidemia primary prevention NHS PRODIGY Guidance FDA on Hyperlipidemia primary prevention CDC on Hyperlipidemia primary prevention
Books
Books on Hyperlipidemia primary prevention
News
Hyperlipidemia primary prevention in the news Be alerted to news on Hyperlipidemia primary prevention News trends on Hyperlipidemia primary prevention
Commentary
Blogs on Hyperlipidemia primary prevention
Definitions
Definitions of Hyperlipidemia primary prevention
Patient Resources / Community
Patient resources on Hyperlipidemia primary prevention Discussion groups on Hyperlipidemia primary prevention Patient Handouts on Hyperlipidemia primary prevention Directions to Hospitals Treating Hyperlipidemia primary prevention Risk calculators and risk factors for Hyperlipidemia primary prevention
Healthcare Provider Resources
Symptoms of Hyperlipidemia primary prevention Causes & Risk Factors for Hyperlipidemia primary prevention Diagnostic studies for Hyperlipidemia primary prevention Treatment of Hyperlipidemia primary prevention
Continuing Medical Education (CME)
CME Programs on Hyperlipidemia primary prevention
International
Hyperlipidemia primary prevention en Espanol Hyperlipidemia primary prevention en Francais
Business
Hyperlipidemia primary prevention in the Marketplace Patents on Hyperlipidemia primary prevention
Experimental / Informatics
List of terms related to Hyperlipidemia primary prevention

Overview

Children and adolescents with high-risk hyperlipidemia require lipid-lowering drug therapy, particularly those with familial hypercholesterolemia, despite compliance with lifestyle recommendations.

Primary Prevention

United States Preventive Services Task Force (USPSTF) screening for lipid disorders in adults(DONOT EDIT)

“

Screening Men The USPSTF strongly recommends screening men aged 35 and older for lipid disorders. This is a grade A recommendation. The USPSTF recommends screening men aged 20 to 35 for lipid disorders if they are at increased risk for CHD. This is a grade B recommendation. Screening Women at Increased Risk The USPSTF strongly recommends screening women aged 45 and older for lipid disorders if they are at increased risk for CHD. This is a grade A recommendation. The USPSTF recommends screening women aged 20 to 45 for lipid disorders if they are at increased risk for CHD. This is a grade B recommendation. Screening of Young Men and All Women Not at Increased Risk The USPSTF makes no recommendation for or against routine screening for lipid disorders in men aged 20 to 35, or in women aged 20 and older who are not at increased risk for CHD. This is a grade C recommendation. Clinical Considerations An age to stop screening has not been established. Screening may be appropriate in older people who have never been screened; repeated screening is less important in older people because lipid levels are less likely to increase after age 65. However, because older adults have an increased baseline risk for coronary heart disease, they stand to gain greater absolute benefit from the treatment of dyslipidemia, compared with younger adults.

”

References

Template:WikiDoc Sources